How Gut Bacteria Inject Proteins Into Your Cells

Molecular Syringes Inside Your Gut

For decades, scientists assumed that the microscopic syringes bacteria use to shoot proteins into human cells belonged exclusively to pathogens—disease-causing invaders like Salmonella and Shigella. A landmark study published in Nature Microbiology has overturned that assumption. Researchers found that roughly 80 percent of Pseudomonadota living peacefully in healthy human guts carry fully functional type III secretion systems (T3SS)—the same syringe-like apparatus pathogens use to hijack cells.

The discovery suggests that our resident microbes are far more than passive bystanders. They are actively communicating with our bodies at the molecular level, injecting proteins that influence immunity and metabolism.

What Is a Type III Secretion System?

A type III secretion system is a nanoscale protein machine, roughly 25 to 30 different bacterial proteins assembling into a structure that weighs more than six million daltons. Structurally, it resembles a hollow needle mounted on a base that spans the bacterium's double membrane. The needle punches through the host cell's outer membrane and creates a direct channel from the bacterium's interior into the human cell's cytoplasm.

Proteins called effectors travel through the hollow needle in an unfolded state, threading through a molecular gate formed by a ring of methionine residues that dilates to let them pass. Once inside the host cell, these effectors refold and begin interacting with human proteins, altering signaling pathways that control inflammation, cell survival, and nutrient processing.

According to a review in Nature Reviews Microbiology, the T3SS evolved from the bacterial flagellum—the spinning tail bacteria use to swim. Over evolutionary time, the export machinery was repurposed from propulsion into a precision delivery device.

Friendly Fire: Why Harmless Bacteria Carry Weapons

The Helmholtz Munich–led team, working with Ludwig Maximilians University and Aix-Marseille University, used machine learning to predict which proteins commensal bacteria inject and then mapped over a thousand interactions between those effectors and human proteins. The results showed a clear pattern: commensal effectors preferentially target pathways involved in immune regulation and metabolic control.

Crucially, the effectors from harmless bacteria look structurally different from those wielded by pathogens. Where pathogenic effectors sabotage the cell to help the invader survive, commensal effectors appear to modulate the immune system more gently—dampening excessive inflammation or fine-tuning nutrient-sensing signals.

Links to Disease

The study also examined what happens when this molecular dialogue goes wrong. Using metagenomic data from patients with inflammatory bowel disease, the researchers found that genes encoding T3SS effectors were enriched in Crohn's disease but depleted in ulcerative colitis. The genetic neighborhoods targeted by these effectors overlap with human gene variants already linked to autoimmune and metabolic conditions.

This finding opens a new avenue for understanding chronic gut inflammation. Rather than simply cataloging which bacterial species live in the gut, scientists can now ask which molecular messages those bacteria are sending—and whether misdelivered or excessive effector injection triggers disease.

Why It Matters Beyond the Gut

The implications reach beyond gastroenterology. If commensal bacteria routinely inject immune-modulating proteins into human cells, it could reshape how researchers approach probiotics, autoimmune therapies, and even drug delivery. Bioengineers have already begun experimenting with modified T3SS as programmable protein-delivery platforms, essentially turning bacteria into living syringes that can deposit therapeutic molecules inside target cells.

For patients, the research underscores a simple truth: the microbiome is not a passive ecosystem. It is a dynamic, protein-injecting partner whose molecular conversations with our cells are just beginning to be decoded.